Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets (NCT07671911)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nalbuphine Extended-Release Tablets for the Treatment of Chronic Cough in Participants With Idiopathic Pulmonary Fibrosis
🩺 Plain-English Summary (8th-Grade Level)
The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with Idiopathic Pulmonary Fibrosis (IPF).
Who can join: Review the eligibility criteria below.
Location: Pulmonary Specialists of The Palm Beaches — Loxahatchee Groves, Florida
Age range: 40 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- Pulmonary Specialists of The Palm Beaches — Loxahatchee Groves, Florida
- Clinical Research and Associates, Inc. — Miami, Florida
- Clinical Research of Gastonia (CRG) — Gastonia, North Carolina
- El Paso Pulmonary Association, PA — El Paso, Texas
- Elevate Clinical Research — Houston, Texas
📞 Contact the Study Coordinator
Phone: (203) 304-2499
Email: Paula.Buckley@trevitherapeutics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Idiopathic Pulmonary Fibrosis
- Atezolizumab for Idiopathic Pulmonary Fibrosis — Los Angeles, California
- A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) — Quilmes, Buenos Aires
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis — Birmingham, Alabama
- LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) — Birmingham, Alabama
- Yoga Effect on Quality of Life Study Among Patients with Idiopathic Pulmonary Fibrosis — Seattle, Washington
- MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) — Camperdown, New South Wales
Explore by condition: All Idiopathic Pulmonary Fibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.